PTO/SB/24 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/718,262 Filing Date November 20, 2003 First Named Inventor Paul B. McCray, Jr. et al. Art Unit 1636 **Examiner Name** David Guzo correspondence after initial filing) Attorney Docket Number 17023.035US1 nber of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final **Provisional Application** Proprietary Information Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please Identify, **Terminal Disclaimer Extension of Time Request** below): Form 1449 (2 pgs.); Copies of 19 cited Request for Refund Express Abandonment Request references; Comm. Concerning Related Applications (1 pg.); Check for \$180.00 for CD, Number of CD(s) Information Disclosure Statement IDS fee; return postcard Landscape Table on CD Certified Copy of Priority Remarks Document(s)

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name
VIKSNINS HARRIS & PAPYS PLLP

Signature

Printed name
Peter L. Malen

Date
April 10, 2006

Reg. No. 44,894

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Typed or printed name Lynda Mau

Reply to Missing Parts/ Incomplete Application

Reply to Missing Parts under 37 CFR 1.52 or 1.53

Myma I Vais

Date

April 10, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

S/N 10/718,262

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Paul B. McCray, Jr. et al.

Examiner:

David Guzo

Serial No.:

10/718,262

Group Art Unit:

1636

Filed:

November 20, 2003

Docket:

17023.035US1

Title:

METHODS FOR PRODUCING AND USING IN VIVO PSEUDOTYPED

RETROVIRUSES USING ENVELOPE GLYCOPROTEINS FROM LYMPHOCYTIC

CHORIOMENINGITIS VIRUS (LCMV)

COMMUNICATION CONCERNING RELATED APPLICATIONS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants would like to bring to the Examiner's attention the following related application.

Applications that claim priority to the related application may be filed, and Applicants respectfully request that the Examiner review those applications prior to issuing a Notice of Allowance in the present application.

Application Number	Filing Date	Docket Number	
10/993,319	November 19, 2004	17023.051US1	

Respectfully submitted, Paul B. McCray, Jr. et al. By their Representatives, Viksnins Harris & Padys PLLP P.O. Box 111098

Saint Paul, MN 551/1

952 876-4094

Date Mri (10, 200)

By

Peter L. Malen Reg. No. 44,894

Lynda Mau

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Paul B. McCray, Jr. et al.

Examiner:

David Guzo

Serial No.:

10/718,262

Group Art Unit:

1636

Riled:

Docket:

November 20, 2003

17023.035US1

RETROVIRUSES USING ENVELOPE GLYCOPROTEINS FROM LYMPHOCYTIC

METHODS FOR PRODUCING AND USING IN VIVO PSEUDOTYPED

CHORIOMENINGITIS VIRUS (LCMV)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

An Information Disclosure Statement filing fee of \$180.00 is enclosed herewith. The Commissioner is hereby authorized to charge any additional required fees to Deposit Account No. 503503 in order to have this Information Disclosure Statement considered. The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

> Respectfully submitted, Paul B. McCray, Jr. et al.

By their Representatives, Viksnins Harris & Padys PLLP

P.O. Box 111098

Saint Paul, MN 55111

952 876-409/

01 FC:1806

180.00 OP

04/14/2006 SFELEKE1 00000091 10718262

Peter L. Malen Reg. No. 44,894

CERTIFICATE UNDER 37 CFR 1.8: I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment; Commissioner for Patents; P.O. Box 1450, Alexandria, VA 22313-1450, on this day of April, 2006.



Application Number	10/718,262	
Filing Date	November 20, 2003	
First Named Inventor	McCray	
Group Art Unit	1636	
Examiner Name	David Guzo	

Sheet 1 of 2

Attorney Docket No: 17023.035US1

US PATENT DOCUMENTS			
Examiner US Document Publication Date Name of Patentee/Applicant of Document Initials * Number		Name of Patentee/Applicant of Document	
	6,440,730	August 27, 2002	Von Laer et al.
,,	6,555,107	April 29, 2003	Poeschla et al.
	2005/0123517	June 09, 2005	McCray, Jr. et al.

FOREIGN PATENT DOCUMENTS			
Examiner Initials*	Foreign Document Number (include country code)	Publication Date	Translation (Abstract Only or Full Translation, if applicable)
	WO 03/092582	November 13, 2003	
	EP 1 006 196	June 07, 2000	Abstract

	OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Include last name of the first author (in CAPITAL letters), "Title of the Article", <u>Title of the Source</u> (book, magazine, journal, serial, symposium, catalog, etc.), <u>Volume-Number</u> , page(s) and (date).
	International Search Report from PCT application serial number PCT/US2004/39076, mailed April 20, 2005.
	Azzouz et al., "Lentiviral vectors for treating and modeling human CNS disorders", <u>J Gene Med</u> , <u>6(9)</u> , 951-962 (2004).
	Besnard et al., "Multiple interacting sites regulate astrocyte-specific transcription of the human gene for glial fibrillary acidic protein", <u>J Biol Chem</u> , <u>266(28)</u> , 18877-18883 (1991).
	Blömer et al., "Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector", <u>J Virol</u> , <u>71(9)</u> , 6641-6649 (1997).
	Brooks et al., "Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors", <u>PNAS</u> , <u>99(9)</u> , 6216-6221 (2002).
	Burton et al., "Gene therapy progress and prospects: Parkinson's disease", <u>Gene Ther</u> , <u>10(20)</u> , 1721-1727 (2003).
	Dylla et al., "Improved apical airway epithelia targeting properties of FIV vector pseudotyped with envelopes from LCMV", Molecular Therapy, 9, Supplement 1, page S186, abstract 491, (2004).
	Hsich et al., "Critical issues in gene therapy for neurologic disease", <u>Hum Gene Ther</u> , <u>13(5)</u> , 579-604 (2002).
	Loewen et al., "Transgene-specific toxicity in lentiviral vector-transduced feline TM in vivo", ARVO Annual Meeting Abstract Search and Program Planner, abstract 1147, Annual Meeting of the Association for Research in Vision and Opthalmology, Fort Lauderdale, FL, USA, May 04-08, 2003 (2003).
	Petreanu et al., "Maturation and death of adult-born olfactory bulb granule neurons: Role of olfaction", <u>J Neurosci</u> , <u>22(14)</u> , 6106-6113 (2002).
	Rainov et al., "Clinical trials with retrovirus mediated gene therapy - what have we learned?", <u>J Neurooncol</u> , <u>65(3)</u> , 227-236 (2003).
	Sinnayah et al., "Targeted viral delivery of Cre recombinase induces conditional gene deletion in cardiovascular circuits of the mouse brain", Physiol Genomics , 18(1) , 25-32 (2004).

EXAMINER

DATE CONSIDERED

Substitute for form 1449A/PTO and/or 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/718,262
	Filing Date	November 20, 2003
	First Named Inventor	McCray
	Group Art Unit	1636
	Examiner Name	David Guzo
Sheet 2 of 2	Attorney Docket No: 1	7023.035US1

	OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Include last name of the first author (in CAPITAL letters), "Title of the Article", <u>Title of the Source</u> (book, magazine, journal, serial, symposium, catalog, etc.), <u>Volume-Number</u> , page(s) and (date).
	Stein et al., "Gene transfer to the brain using feline immunodeficiency virus-based lentivirus vectors", Methods Enzymol, 346, 433-454 (2002).
	Stein et al., "The lymphocytic choriomeningitis virus envelope glycoprotein targets lentiviral gene transfer vector to neural progenitors in the murine brain", Mol Ther, 11(3), 382-389 (2005).
,	Verma et al., "Gene therapy promises, problems and prospects", Nature, 389(6648), 239-242 (1997).
	Wichterle et al., "Direct evidence for homotypic, glia-independent neuronal migration", Neuron, 18(5), 779-791 (1997).
	Wong et al., "Transduction patterns of pseudotyped lentiviral vectors in the nervous system", Mol Ther, 9(1), 101-111 (2004).